HEALTHIER CHINA THROUGH INNOVATION

Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 45 member companies with pharmaceutical R&D capability.


RDPAC Announces 13-New Executive Committee Members for 2022-2023

September 24, 2021
Beijing, September 24, 2021 – The R&D-based Pharmaceutical Association Committee (RDPAC) announces a great news on its newly-elected Executive Committee Members for 2022-2023.

“The 4th Sub-report of Fostering China Pharmaceutical Innovation System: Promote Simultaneous R&D, Registration and Review of Innovative Drugs” Released

September 15, 2021
Through joint efforts of PhIRDA and RDPAC, the “Fostering China Pharmaceutical Innovation System Report 4: Promote Simultaneous R&D, Registration and Review of Innovative Drugs” is officially released today.

2021 PhRMA -RDPAC Joint China Strategy Session Successfully Held

July 07, 2021
PhRMA and RDPAC, together with EFPIA, JPMA and BIO, co-hosted the annual Joint China Strategy Sessions on Science/Regulatory, Intellectual Property and Market Access.

PUBLICATIONS

DEEPENING THE DRUG INNOVATION ECOSYSTEM REFORM – A PLAN TO DESIGN AND BUILD CHINA’S CLINICAL RESEARCH SYSTEM

Health is the common aspiration of all mankind, and a healthy China constitutes an integral part of the “China Dream”.